Özge ÇAKMAK KARAASLAN, Serkan ÜNLÜ, Murat Oğuz ÖZİLHAN, Salih TOPAL, Atiye ÇENGEL, Serkan BULGUROĞLU

Akut Miyokart Enfarktüsünde Farklı Revaskülarizasyon Yöntemlerinin Sol Ventrikül Fonksiyonları ve Serum sST2 Düzeyleri ile İlişkisi

Amaç: Akut miyokart enfarktüsü (AME) ile başvuran hastalarda, farklı revaskülarizasyon yöntemlerinin çözülebilir ST2 (sST2) düzeyleri ve solventrikül sistol ile diyastol ekokardiyografik parametreleri üzerine olan etkilerini araştırdık.Gereç ve Yöntem: Çalışmaya toplam 30 hasta dahil edildi. Çalışma popülasyonu iki gruba ayrıldı. AME ile başvuran primer perkütan girişim (PKG)uygulanan veya fibrinolitik uygulanan hastalar çalışma gruplarını oluşturdu. sST2 ve ekokardiyografi parametreler hastaların 3 aylık izlemi boyuncakarşılaştırıldı.Bulgular: Her iki grupta sST2 düzeyi arasında fark izlenmedi. Sol ventrikül ejeksiyon fraksiyonu (SVEF) PKG yapılan grupta daha yüksek saptandı.Sonuç: sST2 düzeyi AME hastalarında revaskülarizasyon yönteminden bağımsız olarak değişiklik göstermedi. PKG grubunda fibrinolitik grubunakıyasla SVEF anlamlı olarak daha yüksek bulundu.

The Association Between Different Revascularization Methods and Left Ventricular Functions and Serum sST2 Levels in Patients with Acute Myocardial Infarction

Objectives: We investigated the effects of different revascularization methods on soluble ST2 (sST2) levels and echocardiographic parameters of left ventricular systole and diastolic in patients admitted with acute myocardial infarction (AMI). Materials and Methods: A total of 30 patients were included in the study. The study population was divided into two groups. Patients who underwent primary percutaneous intervention (PCI) or fibrinolytic therapy admitted with AMI were formed the study groups. sST2 and echocardiography parameters were compared during 3-month follow-up of patients. Results: There was no difference between sST2 levels in both groups. Left ventricular ejection fraction (LVEF) was higher in the PCI group. Conclusion: Consequently, the sST2 level did not change in AMI patients regardless of the revascularization method. LVEF was significantly higher in the PCI group compared to the fibrinolytic group.

PDF

___

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151.
2. Glasser SP. The time course of left ventricular remodeling after acute myocardial infarction. The American journal of cardiology. 1997;80:506- 507.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
4. Januzzi JL, Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. Journal of cardiovascular translational research. 2013;6:493-500. 5. Ahmad T, Fiuzat M, Felker GM, et al. Novel biomarkers in chronic heart failure. Nature reviews Cardiology. 2012;9:347-359.
6. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2018;39:119-177.
7. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. The New England journal of medicine. 2009;360:2705-2718.
8. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet (London, England). 2008;371:559-568.
9. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of STelevation myocardial infarction). J Am Coll of Cardiol. 2010;55:102-110.
10. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2003;16:1091-1110.
11. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138:e618-e651.
12. Schernthaner C, Lichtenauer M, Wernly B, et al. Multibiomarker analysis in patients with acute myocardial infarction. Eur j Clin Invest. 2017;47:638- 648.
13. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259-267.
14. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation Heart failure. 2011;4:180-187.
15. Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clinical chemistry. 2014;60:530-540.
16. Abston ED, Barin JG, Cihakova D, et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circulation: Heart Failure. 2012;5:366-375.
17. Fertin M, Dubois E, Belliard A, et al. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol. 2012;110:277-283.
18. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243-250.
19. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. European journal of heart failure. 2011;13:718-725.
20. Jha D, Goenka L, Ramamoorthy T, et al. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur j Clin Invest. 2018;48:e12994.
21. Ho JE, Chen WY, Chen MH, et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest. 2013;123:4208-4218.
22. Yin H, Huang BJ, Yang H, et al. Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochemical and biophysical research communications. 2006;351:940-946.
23. Fagundes CT, Amaral FA, Souza AL, et al. ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. Journal of leukocyte biology. 2007;81:492-499.